^
    No biomarker
    Malignant Pleural Mesothelioma
    nivolumab + ipilimumab
    Sensitive: A1 - Approval
    No biomarker
    Malignant Pleural Mesothelioma
    pemetrexed
    Sensitive: A1 - Approval
    No biomarker
    Malignant Pleural Mesothelioma
    carboplatin + pemetrexed
    Sensitive: A2 - Guideline
    No biomarker
    Malignant Pleural Mesothelioma
    nivolumab
    Sensitive: A2 - Guideline
    No biomarker
    Malignant Pleural Mesothelioma
    bevacizumab
    Sensitive: A2 - Guideline
    No biomarker
    Malignant Pleural Mesothelioma
    pembrolizumab
    Sensitive: A2 - Guideline
    No biomarker
    Malignant Pleural Mesothelioma
    cisplatin + pemetrexed
    Sensitive: A2 - Guideline
    No biomarker
    Mesothelioma
    GC
    Sensitive: A2 - Guideline
    No biomarker
    Mesothelioma
    bevacizumab
    Sensitive: A2 - Guideline
    No biomarker
    Mesothelioma
    cisplatin + raltitrexed
    Sensitive: A2 - Guideline
    No biomarker
    Mesothelioma
    nivolumab
    Sensitive: A2 - Guideline
    No biomarker
    Malignant Pleural Mesothelioma
    carboplatin + raltitrexed
    Sensitive: A2 - Guideline
    No biomarker
    Malignant Pleural Mesothelioma
    GC
    Sensitive: A2 - Guideline
    No biomarker
    Malignant Pleural Mesothelioma
    gemcitabine
    Sensitive: A2 - Guideline
    No biomarker
    Malignant Pleural Mesothelioma
    vinorelbine tartrate
    Sensitive: A2 - Guideline
    No biomarker
    Malignant Pleural Mesothelioma
    ramucirumab
    Sensitive: A2 - Guideline
    High 4-gene inflammatory score
    Mesothelioma
    nivolumab + ipilimumab
    Sensitive: B - Late Trials
    PD-L1 expression
    Malignant Pleural Mesothelioma
    nivolumab
    Sensitive: C1 - Off-label
    BRCA1 mutation
    Mesothelioma
    rucaparib
    Sensitive: C1 - Off-label
    BAP1 mutation
    Mesothelioma
    tazemetostat
    Sensitive: C2 – Inclusion Criteria
    MSLN positive
    Mesothelioma
    TC-210
    Sensitive: C2 – Inclusion Criteria
    WT1 expression
    Malignant Pleural Mesothelioma
    nivolumab + galinpepimut-S
    Sensitive: C3 – Early Trials
    TMB-L
    Malignant Pleural Mesothelioma
    PD1 inhibitor
    Resistant: C3 – Early Trials
    TMB-L
    Malignant Pleural Mesothelioma
    PD-L1 inhibitor
    Resistant: C3 – Early Trials
    PD-L1 underexpression
    Malignant Pleural Mesothelioma
    PD1 inhibitor
    Resistant: C3 – Early Trials
    BAP1 negative + BRCA1 mutation
    Mesothelioma
    rucaparib
    Sensitive: C3 – Early Trials
    BAP1 negative
    Mesothelioma
    rucaparib
    Sensitive: C3 – Early Trials
    MRE11A mutation
    Mesothelioma
    olaparib
    Sensitive: C3 – Early Trials
    BAP1 mutation
    Mesothelioma
    olaparib
    Resistant: C3 – Early Trials
    BRCA1 negative
    Mesothelioma
    rucaparib
    Sensitive: C3 – Early Trials
    BAP1 mutation
    Mesothelioma
    rucaparib
    Sensitive: C3 – Early Trials
    ERCC1 expression
    Malignant Pleural Mesothelioma
    GC
    Sensitive: C3 – Early Trials
    RRM1 expression
    Malignant Pleural Mesothelioma
    GC
    Sensitive: C3 – Early Trials
    MSLN overexpression
    Malignant Pleural Mesothelioma
    TC-210
    Sensitive: C3 – Early Trials
    ASS1 mutation
    Malignant Pleural Mesothelioma
    cisplatin + pemetrexed + pegargiminase
    Sensitive: C3 – Early Trials
    PD-L1 overexpression
    Mesothelioma
    pembrolizumab + nintedanib
    Sensitive: C3 – Early Trials
    CDKN2A negative
    Mesothelioma
    abemaciclib
    Sensitive: C3 – Early Trials
    PD-L1 overexpression
    Malignant Pleural Mesothelioma
    nivolumab
    Sensitive: C4 – Case Studies
    EML4-ALK I1171N + EML4-ALK L1196M + EML4-ALK G1202R
    Mesothelioma
    lorlatinib
    Resistant: C4 – Case Studies
    EML4-ALK I1171N + EML4-ALK L1196M
    Malignant Pleural Mesothelioma
    alectinib
    Resistant: C4 – Case Studies
    STRN-ALK rearrangement
    Mesothelioma
    crizotinib
    Sensitive: C4 – Case Studies
    STRN exon 2-ALK exon 20 fusion
    Mesothelioma
    cisplatin + pemetrexed
    Resistant: C4 – Case Studies
    TMB-L + BAP1 V99M + NF2 R34 + Chr del(14q) + Chr del(19q)
    Mesothelioma
    pembrolizumab
    Sensitive: C4 – Case Studies
    TMB-L + BAP1 V99M + NF2 R34 + Chr del(14q) + Chr del(19q)
    Mesothelioma
    cisplatin + carboplatin + pemetrexed + mitomycin
    Resistant: C4 – Case Studies
    STRN-ALK rearrangement
    Mesothelioma
    ABT 263
    Sensitive: D – Preclinical
    STRN-ALK rearrangement
    Mesothelioma
    cobimetinib
    Sensitive: D – Preclinical
    STRN-ALK rearrangement
    Mesothelioma
    ceritinib + PF-05212384
    Sensitive: D – Preclinical
    STRN-ALK rearrangement
    Mesothelioma
    ensartinib
    Sensitive: D – Preclinical
    STRN-ALK rearrangement
    Mesothelioma
    trametinib
    Sensitive: D – Preclinical
    STRN-ALK rearrangement
    Mesothelioma
    cobimetinib + ceritinib
    Sensitive: D – Preclinical
    STRN-ALK rearrangement
    Mesothelioma
    ceritinib
    Sensitive: D – Preclinical
    STRN-ALK rearrangement
    Mesothelioma
    brigatinib
    Sensitive: D – Preclinical
    STRN-ALK rearrangement
    Mesothelioma
    cisplatin + gemcitabine
    Resistant: D – Preclinical
    NF2 mutation
    Mesothelioma
    CBL0102
    Sensitive: D – Preclinical
    RB1 deletion
    Mesothelioma
    BI 6727
    Sensitive: D – Preclinical
    RB1 deletion
    Mesothelioma
    MLN8237
    Sensitive: D – Preclinical
    NF2 mutation
    Mesothelioma
    verteporfin
    Sensitive: D – Preclinical
    LATS1 mutation
    Mesothelioma
    verteporfin
    Sensitive: D – Preclinical
    LATS2 mutation
    Mesothelioma
    verteporfin
    Sensitive: D – Preclinical
    RASSF7 amplification
    Mesothelioma
    verteporfin
    Sensitive: D – Preclinical
    MSLN overexpression + PD-L1 overexpression
    Mesothelioma
    ATA3271
    Sensitive: D – Preclinical
    KRAS mutation
    Mesothelioma
    IK-930
    Sensitive: D – Preclinical
    EGFR mutation
    Mesothelioma
    IK-930
    Sensitive: D – Preclinical